keyword
MENU ▼
Read by QxMD icon Read
search

paclitaxel cancer

keyword
https://www.readbyqxmd.com/read/29456682/l1cam-promotes-epithelial-to-mesenchymal-transition-and-formation-of-cancer-initiating-cells-in-human-endometrial-cancer
#1
Jinlong Chen, Fufeng Gao, Naifu Liu
Identification of novel factors critical for epithelial to mesenchymal transition (EMT) and cancer initiating cell (CIC) formation may aid in the identification of novel therapeutics for the treatment of endometrial cancer. The present study demonstrated that L1 cell adhesion molecule (CAM) is critical for EMT and formation of CICs in endometrial cancer. Overexpression of L1CAM may promote EMT with increased formation of CICs in HEC-1A endometrial cancer cells. CICs and mesenchymal status resist chemotherapeutic drugs and may regenerate the various cell types in tumors, thereby resulting in relapse of the disease...
March 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29454514/phase-2-study-evaluating-intermittent-and-continuous-linsitinib-and-weekly-paclitaxel-in-patients-with-recurrent-platinum-resistant-ovarian-epithelial-cancer
#2
Amit Oza, Stanley Kaye, Jan Van Tornout, Cristiana Sessa, Martin Gore, R Wendel Naumann, Hal Hirte, Nicoletta Colombo, Jihong Chen, Seema Gorla, Srinivasu Poondru, Margaret Singh, Joyce Steinberg, Geoff Yuen, Susana Banerjee
BACKGROUND: Linsitinib, an oral, dual inhibitor of insulin-like growth factor-1 receptor and insulin receptor, in combination with weekly paclitaxel, may improve clinical outcomes compared with paclitaxel alone in patients with refractory or platinum-resistant ovarian cancer. PATIENTS AND METHODS: This open-label phase 1/2 clinical trial (NCT00889382) randomized patients with refractory or platinum-resistant ovarian cancer (1:1:1) to receive either oral intermittent linsitinib (600mg once daily on Days 1-3 per week) combined with paclitaxel (80mg/m2 on Days 1, 8, and 15; Arm A) or continuous linsitinib (150mg twice daily) in combination with paclitaxel (Arm B), or paclitaxel alone (Arm C)...
February 14, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29454064/rna-based-micelles-a-novel-platform-for-chemotherapeutic-drug-loading-and-delivery
#3
Yi Shu, Hongran Yin, Mehdi Rajabi, Hui Li, Mario Vieweger, Sijin Guo, Dan Shu, Peixuan Guo
RNA can serve as powerful building blocks for bottom-up fabrication of nanostructures for biotechnological and biomedical applications. In addition to current self-assembly strategies utilizing base pairing, motif piling and tertiary interactions, we reported for the first time to build RNA based micellar nanoconstruct with a cholesterol molecule conjugated onto one helical end of a branched pRNA three-way junction (3WJ) motif. The resulting amphiphilic RNA micelles consist of a hydrophilic RNA head and a covalently linked hydrophobic lipid tail that can spontaneously assemble in aqueous solution via hydrophobic interaction...
February 14, 2018: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/29452759/feasibility-study-of-weekly-nanoparticle-albumin-bound-paclitaxel-150-mg-m-2-followed-by-fluorouracil-epirubicin-and-cyclophosphamide-therapy-as-neoadjuvant-chemotherapy-for-her2-negative-breast-cancer
#4
Yasuyuki Kojima, Hisanori Kawamoto, Toru Nishikawa, Ryosuke Hayami, Arata Shimo, Ei Haku, Kyoko Akiyama, Koichiro Tsugawa
BACKGROUND: Although several studies have shown efficacy of nanoparticle albumin-bound (nab) paclitaxel use as a neoadjuvant treatment in breast cancer, dosage and schedules were varied or used in combination and the data are still limited for weekly regimens. We evaluated the feasibility of weekly nab-paclitaxel followed by FEC (5-FU [fluorouracil], epirubicin, and cyclophosphamide) treatment feasibility as neoadjuvant chemotherapy for breast cancer. PATIENTS AND METHODS: Thirty-three patients with no previous chemotherapy were enrolled to receive nab-paclitaxel 150 mg/m 2 the first 3 of 4 weeks (3q4w) followed by FEC as neoadjuvant treatment...
January 11, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29452344/overexpression-of-blm-promotes-dna-damage-and-increased-sensitivity-to-platinum-salts-in-triple-negative-breast-and-serous-ovarian-cancers
#5
N J Birkbak, Y Li, S Pathania, A Greene-Colozzi, M Dreze, C Bowman-Colin, Z Sztupinszki, M Krzystanek, M Diossy, N Tung, P D Ryan, J E Garber, D P Silver, J D Iglehart, Z C Wang, D Szuts, Z Szallasi, A L Richardson
Background: Platinum based therapy is an effective treatment for a subset of triple negative breast cancer and ovarian cancer patients. In order to increase response rate and decrease unnecessary use, robust biomarkers that predict response to therapy are needed. Patients and methods: We performed an integrated genomic approach combining differential analysis of gene expression and DNA copy number in sensitive compared to resistant triple negative breast cancers in two independent neoadjuvant cisplatin treated cohorts...
February 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29452092/microrna-630-inhibitor-sensitizes-chemoresistant-ovarian-cancer-to-chemotherapy-by-enhancing-apoptosis
#6
Kyung Jin Eoh, So Hyun Lee, Hee Jung Kim, Jung-Yun Lee, Sunghoon Kim, Sang Wun Kim, Young Tae Kim, Eun Ji Nam
MicroRNA-630 (miR-630) has been implicated in the development and progression of multiple cancers. The current study aimed to investigate the role of miR-630 in chemoresistant epithelial ovarian cancer. MiR-630 expression levels were detected in ovarian cancer cell line SKOV3 and paclitaxel-resistant SKOV3 (SKOV3-TR) via microarray and qRT-PCR. MiR-630 inhibitors and negative controls were transfected into SKOV3 and SKOV3-TR cells. Wound healing, invasion, chemosensitivity, and cell apoptosis assays were performed to determine proliferation and migration rates...
February 13, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29451777/filomicelles-deliver-a-chemo-differentiation-combination-of-paclitaxel-and-retinoic-acid-that-durably-represses-carcinomas-in-liver-to-prolong-survival
#7
Praful Nair, Cory Alvey, Xiaoling Jin, Jerome Irianto, Irena Ivanovska, Dennis E Discher
Drug resistance and relapse is common in cancer treatments with chemotherapeutics, and while drug combinations with naturally occurring, differentiation-inducing retinoic acid (RA) are highly successful against one type of liquid tumor, solid tumors present major problems for delivery. Here, inspired by filoviruses that can be microns in length, flexible filomicelles that self-assemble from an amphiphilic block copolymer (PEG-PCL) are shown to effectively deliver RA and paclitaxel (TAX) to several solid tumor models, particularly in liver...
February 16, 2018: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/29450802/mhi-148-cyanine-dye-conjugated-chitosan-nanomicelle-with-nir-light-trigger-release-property-as-cancer-targeting-theranostic-agent
#8
Reju George Thomas, Myeong Ju Moon, Suchithra Poilil Surendran, Hyeong Ju Park, In-Kyu Park, Byeong-Il Lee, Yong Yeon Jeong
PURPOSE: Paclitaxel (PTX) loaded hydrophobically modified glycol chitosan (HGC) micelle is biocompatible in nature, but it requires cancer targeting ability and stimuli release property for better efficiency. To improve tumor retention and drug release characteristic of HGC-PTX nanomicelles, we conjugated cancer targeting heptamethine dye, MHI-148, which acts as an optical imaging agent, targeting moiety and also trigger on-demand drug release on application of NIR 808 nm laser. PROCEDURES: The amine group of glycol chitosan modified with hydrophobic 5β-cholanic acid and the carboxyl group of MHI-148 were bonded by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide chemistry...
February 15, 2018: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/29449189/adjuvant-chemoradiotherapy-versus-radiotherapy-alone-for-women-with-high-risk-endometrial-cancer-portec-3-final-results-of-an-international-open-label-multicentre-randomised-phase-3-trial
#9
Stephanie M de Boer, Melanie E Powell, Linda Mileshkin, Dionyssios Katsaros, Paul Bessette, Christine Haie-Meder, Petronella B Ottevanger, Jonathan A Ledermann, Pearly Khaw, Alessandro Colombo, Anthony Fyles, Marie-Helene Baron, Ina M Jürgenliemk-Schulz, Henry C Kitchener, Hans W Nijman, Godfrey Wilson, Susan Brooks, Silvestro Carinelli, Diane Provencher, Chantal Hanzen, Ludy C H W Lutgens, Vincent T H B M Smit, Naveena Singh, Viet Do, Romerai D'Amico, Remi A Nout, Amanda Feeney, Karen W Verhoeven-Adema, Hein Putter, Carien L Creutzberg
BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. METHODS: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup...
February 12, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29448632/mpeg-cs-bmi-1rnai-nanoparticles-synthesis-and-its-targeted-inhibition-effect-on-cd133-laryngeal-stem-cells
#10
Xudong Wei, Jian He, Jingyu Wang, Wei Wang
Previous studies have confirmed that CD133+ cells in laryngeal tumor tissue have the characteristics of cancer stem cells. Bmi-1 gene expression is central to the tumorigenicity of CD133+ cells. In this study, we tried to develop a new siRNA carrier system using chitosan-methoxypolyethylene nanoparticles (CS-mPEG-NPs) that exhibit higher tumor-targeting ability and enhanced gene silencing efficacy in CD133+ tumor stem cells. It is hoped to block the self-renewal and kill the stem cells of laryngeal carcinoma...
March 1, 2018: Journal of Nanoscience and Nanotechnology
https://www.readbyqxmd.com/read/29445928/efficacy-and-safety-of-trastuzumab-lapatinib-and-paclitaxel-neoadjuvant-treatment-with-or-without-prolonged-exposure-to-anti-her2-therapy-and-with-or-without-hormone-therapy-for-her2-positive-primary-breast-cancer-a-randomised-five-arm-multicentre-open-label
#11
N Masuda, M Toi, N Yamamoto, H Iwata, K Kuroi, H Bando, S Ohtani, T Takano, K Inoue, Y Yanagita, H Kasai, S Morita, T Sakurai, S Ohno
BACKGROUND: Dual blockade of HER2 promises increased pathological complete response (pCR) rate compared with single blockade in the presence of chemotherapy for HER2-positive (+) primary breast cancer. Many questions remain regarding optimal duration of treatment and combination impact of endocrine therapy for luminal HER2 disease. METHODS: We designed a randomised phase II, five-arm study to evaluate the efficacy and safety of lapatinib and trastuzumab (6 weeks) followed by lapatinib and trastuzumab plus weekly paclitaxel (12 weeks) with/without prolongation of anti-HER2 therapy prior to chemotherapy (18 vs...
February 14, 2018: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29445301/comparative-effectiveness-of-early-line-nab-paclitaxel-vs-paclitaxel-in-patients-with-metastatic-breast-cancer-a-us-community-based-real-world-analysis
#12
Reshma L Mahtani, Monika Parisi, Stefan Glück, Quanhong Ni, Siyeon Park, Corey Pelletier, Claudio Faria, Fadi Braiteh
Background: Real-world analyses of treatments for patients with metastatic breast cancer are limited. We evaluated the comparative effectiveness of nab -paclitaxel vs. paclitaxel in patients with metastatic breast cancer using data from an electronic medical record database from community practices across the USA. Methods: We performed a retrospective cohort study using fully de-identified data from an independent US electronic medical record platform of patients with metastatic breast cancer initiating single-agent nab -paclitaxel or paclitaxel as a first- or second-line treatment from December 1, 2010 to October 6, 2014...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29441988/co-administration-of-tlyp-1-with-polymeric-paclitaxel-conjugates-enhanced-intratumoral-accumulation-and-anti-tumor-efficacy
#13
Zheshuo Liu, Zhigang Huang, Liqian Ci, Liu Lu, Zhepeng Liu, Xueying Yan, Zhiqiang Yan, Lei Yu, Yu Liu, Weiyue Lu
BACKGROUND: It has been previously demonstrated that conjugation of paclitaxel to a linear poly(l-γ-glutamylglutamine) backbone can enhance water solubility of paclitaxel. However, intratumoral penetration of the nanoscale poly(l-γ-glutamylglutamine)-paclitaxel conjugate (PGG-PTX) was still limited due to dysfunctional tumor blood vessels as well as high interstitial pressure in the tumor microenvironment. PURPOSE: The objective of the present research was to investigate the feasibility of co-administration of a tumor penetration enhancing peptide tLyp-1 for improving intratumoral accumulation and consequent anti-tumor efficacy of PGG-PTX...
April 1, 2017: Die Pharmazie
https://www.readbyqxmd.com/read/29441454/chemotherapy-and-immunotherapy-for-recurrent-and-metastatic-head-and-neck-cancer-a-systematic-review
#14
REVIEW
Alessandro Guidi, Carla Codecà, Daris Ferrari
Head and neck cancer (HNC) is a fatal malignancy with an overall long-term survival of about 50% for all stages. The diagnosis is not rarely delayed, and the majority of patients present with loco-regionally advanced disease. The rate of second primary tumors after a diagnosis of HNC is about 3-7% per year, the highest rate among solid tumors. Currently, a single-modality or a combination of surgery, radiotherapy and chemotherapy (CHT), is the standard treatment for stage III-IV HNC. For the recurrent/metastatic setting, in the last 40 years great efforts have been made in order to develop a more effective CHT regimen, from the use of methotrexate alone, to the combination of cisplatin (CDDP) and 5-fluorouracile (5FU) or paclitaxel...
February 13, 2018: Medical Oncology
https://www.readbyqxmd.com/read/29441192/knockdown-of-lncrna-mapt-as1-inhibites-proliferation-and-migration-and-sensitizes-cancer-cells-to-paclitaxel-by-regulating-mapt-expression-in-er-negative-breast-cancers
#15
Yiyuan Pan, Yiqi Pan, Yue Cheng, Fan Yang, Zhihan Yao, Ouchen Wang
Background: MAPT-AS1, a long non-coding RNA, has not been reported in any previous research about its function in cancers. In this study, we investigated the role of MAPT-AS1 in the progression and paclitaxel resistance in breast cancer, and the regulation between MAPT-AS1 and its natural comparable sense transcripts MAPT. Methods: We analysed the breast cancer patients' clinical information and explored the function of MAPT-AS1 by gain- and loss-of function assays in vitro and in vivo...
2018: Cell & Bioscience
https://www.readbyqxmd.com/read/29440919/efficacy-and-safety-of-cox-2-inhibitors-for-advanced-non-small-cell-lung-cancer-with-chemotherapy-a-meta-analysis
#16
Ping Dai, Jing Li, Xiao-Ping Ma, Jian Huang, Juan-Juan Meng, Ping Gong
Background: The study of cyclooxygenase-2 (COX-2) inhibitors is now mired in controversy. We performed a meta-analysis to assess the efficacy and safety profile of COX-2 inhibitors in patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: A literature search of PubMed, EMBASE, the Cochrane Central databases, and ClinicalTrials.gov, up until March 26, 2017, identified relevant randomized controlled trials. Data analysis was performed using Stata 12...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29440897/fabrication-of-paclitaxel-hybrid-nanomicelles-to-treat-resistant-breast-cancer-via-oral-administration
#17
Ling-Hui Dian, Ying-Jie Hu, Jia-Ye Lin, Jing-Ying Zhang, Yan Yan, Yi-Nuo Cui, Zhan-Bo Su, Wan-Liang Lu
Aim: Oral chemotherapy using anticancer drugs would improve the clinical practice and the life quality of patients. The aim of the present study was to develop paclitaxel hybrid nanomicelles for oral administration to treat resistant breast cancer. Methods: Evaluations were performed on human breast cancer MCF-7 cells, drug-resistant breast cancer MCF-7/Adr cells, and in MCF-7/Adr-xenografted BALB/c nude mice. The nanomicelles were composed of the polymer soluplus, d-α-tocopheryl polyethyleneglycol 1000 succinate (TPGS 1000 ), and dequalinium (DQA)...
2018: International Journal of Nanomedicine
https://www.readbyqxmd.com/read/29438463/efficacy-and-safety-findings-from-dream-a-phase-iii-study-of-dhp107-oral-paclitaxel-versus-iv-paclitaxel-in-patients-with-advanced-gastric-cancer-after-failure-of-first-line-chemotherapy
#18
Y-K Kang, M-H Ryu, S H Park, J G Kim, J W Kim, S-H Cho, Y-L Park, S R Park, S Y Rha, M J Kang, J Y Cho, S Y Kang, S Y Roh, B-Y Ryoo, B-H Nam, Y-W Jo, K-E Yoon, S C Oh
Background: Paclitaxel is currently only available as an intravenous (IV) formulation. DHP107 is a novel oral formulation of lipid ingredients and paclitaxel. DHP107 demonstrated comparable efficacy, safety, and pharmacokinetics to IV paclitaxel as second-line therapy in patients with advanced gastric cancer (AGC). DREAM is a multicenter, open-label, prospective, randomized phase III study of patients with histologically/cytologically confirmed, unresectable/recurrent AGC after first-line therapy failure...
February 9, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29438316/regulation-of-programmed-death-ligand-1-pd-l1-expression-in-breast-cancer-cell-lines-in-vitro-and-in-immunodeficient-and-humanized-tumor-mice
#19
Eva-Maria Rom-Jurek, Nicole Kirchhammer, Peter Ugocsai, Olaf Ortmann, Anja K Wege, Gero Brockhoff
Programmed death ligand 1 (PD-L1) expression is an efficient strategy of tumor cells to escape immunological eradiation. However, only little is known about the factors that affect the cellular expression levels. Here we assessed the PD-L1 expression on different breast cancer cell lines under standard in vitro culture conditions and as a function of Epirubicin or Paclitaxel treatment. Moreover, we evaluated the expression in immunodeficient tumor mice as well as in humanized tumor mice (i.e., in the presence of a human immune system)...
February 13, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29438092/randomized-phase-ii-trial-of-parsatuzumab-anti-egfl7-or-placebo-in-combination-with-carboplatin-paclitaxel-and-bevacizumab-for-first-line-nonsquamous-non-small-cell-lung-cancer
#20
Joachim von Pawel, David R Spigel, Thomas Ervin, György Losonczy, Fabrice Barlesi, Erzsébet Juhász, Maria Anderson, Bruce McCall, Eric Wakshull, Priti Hegde, Weilan Ye, Daniel Chen, Ilsung Chang, Ina Rhee, Martin Reck
LESSONS LEARNED: The lack of efficacy associated with anti-EGFL7 combined with standard bevacizumab and chemotherapy in this phase II trial in non-small cell lung carcinoma is consistent with the lack of benefit observed in colorectal carcinoma, highlighting the challenge of enhancing the efficacy of VEGF inhibition in unselected populations.Future efforts with agents like anti-EGFL7 should be guided by advances in pharmacodynamic and predictive biomarker development for antiangiogenic agents...
February 7, 2018: Oncologist
keyword
keyword
68450
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"